This medicinal product is for diagnostic use only. E-Z-CAT is indicated for the opacification of the gastro-intestinal tract prior to computerised axial tomography. E-Z-CAT is indicated in adults and children.
Circassia Pharmaceuticals plc announced top-line results from its investigational cat allergy immunotherapy phase III study. In the study, both treatment...
Results of a Phase II clinical study show that a course of just four doses of ToleroMune Cat Allergy therapy...
Purpose: Anticancer agents are known to increase cancer-associated thrombosis (CAT) onset. CAT onset rate is reported to be 1.92% in cisplatin-based therapy, 6.1% in paclitaxel plus ramucirumab combination therapy, and 11.9% in bevacizumab monotherapy.